{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:15:49Z","timestamp":1790691349199,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ctrv.2024.102840","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T13:49:30Z","timestamp":1728654570000},"page":"102840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4839-1215","authenticated-orcid":false,"given":"Miaoying","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangrong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102840_b0005","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394-424.","DOI":"10.3322\/caac.21492"},{"key":"10.1016\/j.ctrv.2024.102840_b0010","article-title":"The current role of adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma","volume":"10","author":"Su","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102840_b0015","unstructured":"NCCN: The NCCN Head and Neck Cancers Clinical Practice Guidelines in Oncology (Version 4.2024). Pennsylvania: NCCN (2024) [Internet]. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"10.1016\/j.ctrv.2024.102840_b0020","doi-asserted-by":"crossref","unstructured":"Pan JJ, Ng WT, Zong JF, Chan LL, O'Sullivan B, Lin SJ, Sze HC, Chen YB, Choi HC, Guo QJ et al: Proposal for the 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 2016, 122(4):546-558.","DOI":"10.1002\/cncr.29795"},{"key":"10.1016\/j.ctrv.2024.102840_b0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.oraloncology.2017.12.004","article-title":"Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study)","volume":"77","author":"Au","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102840_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703995","article-title":"Prognostic factors for overall survival in nasopharyngeal cancer and implication for TNM staging by UICC: A systematic review of the literature","volume":"11","author":"Chiang","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102840_b0035","doi-asserted-by":"crossref","first-page":"e2642","DOI":"10.1097\/MD.0000000000002642","article-title":"Prognostic value of plasma Epstein-Barr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatin-based concurrent chemoradiotherapy in intensity-modulated radiotherapy era","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine"},{"issue":"23","key":"10.1016\/j.ctrv.2024.102840_b0040","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1200\/JCO.2012.46.0816","article-title":"Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography\/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging","volume":"31","author":"Tang","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2024.102840_b0045","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","article-title":"Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma","volume":"94","author":"Chan","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102840_b0050","article-title":"Establishment of a prognostic nomogram for patients with locoregionally advanced nasopharyngeal carcinoma incorporating clinical characteristics and dynamic changes in hematological and inflammatory markers","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102840_b0055","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.21037\/apm-20-2033","article-title":"Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients","volume":"10","author":"Xiong","year":"2021","journal-title":"Ann Palliative Med"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102840_b0060","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.7150\/jca.52539","article-title":"Prognostic efficacy of the combination of the pretreatment systemic Immune-Inflammation Index and Epstein-Barr virus DNA status in locally advanced Nasopharyngeal Carcinoma Patients","volume":"12","author":"Xiong","year":"2021","journal-title":"J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102840_b0065","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.21037\/tcr-23-528","article-title":"A single center retrospective study assessing the prognostic significance of pre-treatment neutrophil\/lymphocyte ratio in locally advanced nasopharyngeal carcinoma","volume":"12","author":"Xu","year":"2023","journal-title":"Transl Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102840_b0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.21037\/atm.2020.01.03","article-title":"Prognostic value of nasopharynx tumour volume in local-regional advanced nasopharyngeal carcinoma","volume":"8","author":"Ni","year":"2020","journal-title":"Ann Translational Med"},{"key":"10.1016\/j.ctrv.2024.102840_b0075","doi-asserted-by":"crossref","unstructured":"Zhou J, Deng Y, Huang Y, Wang Z, Zhan Z, Cao X, Cai Z, Deng Y, Zhang L, Huang H et al: An Individualized Prognostic Model in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Based on Serum Metabolomic Profiling. Life (Basel, Switzerland) 2023, 13(5).","DOI":"10.3390\/life13051167"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102840_b0080","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","article-title":"The basis of oncoimmunology","volume":"164","author":"Palucka","year":"2016","journal-title":"Cell"},{"issue":"10192","key":"10.1016\/j.ctrv.2024.102840_b0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ctrv.2024.102840_b0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.oraloncology.2018.07.011","article-title":"Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer","volume":"84","author":"Lee","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2024.102840_b0095","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2018.02.008","article-title":"Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians","volume":"65","author":"Outh-Gauer","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"20","key":"10.1016\/j.ctrv.2024.102840_b0100","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: The JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102840_b0105","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102840_b0110","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.ctrv.2024.102840_b0115","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.7150\/thno.24387","article-title":"Personalized cancer neoantigen vaccines come of age","volume":"8","author":"Chu","year":"2018","journal-title":"Theranostics"},{"issue":"13","key":"10.1016\/j.ctrv.2024.102840_b0120","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.7150\/thno.53229","article-title":"Neoantigen landscape in metastatic nasopharyngeal carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102840_b0125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/35100512","article-title":"Cross-presentation in viral immunity and self-tolerance","volume":"1","author":"Heath","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2024.102840_b0130","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3389\/fimmu.2018.01643","article-title":"Current concepts of antigen cross-presentation","volume":"9","author":"Embgenbroich","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102840_b0135","doi-asserted-by":"crossref","unstructured":"Xiong Y, Yuan M, Liu Z, Huang J, Bi J, Pi G, Li Y, Li Y, He H, Verma V et al: Long-Term Outcomes of Nasopharyngeal Carcinoma by Epstein-Barr Virus Status in the Chinese Population: A Multicenter Investigation. Journal of clinical medicine 2023, 12(8).","DOI":"10.3390\/jcm12083005"},{"key":"10.1016\/j.ctrv.2024.102840_b0140","doi-asserted-by":"crossref","unstructured":"Tsao SW, Tsang CM, Lo KW: Epstein-Barr virus infection and nasopharyngeal carcinoma. Philosophical transactions of the Royal Society of London Series B, Biological sciences 2017, 372(1732).","DOI":"10.1098\/rstb.2016.0270"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102840_b0145","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1172\/JCI22053","article-title":"Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo","volume":"114","author":"Fu","year":"2004","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102840_b0150","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cncr.28418","article-title":"Epstein-Barr virus nuclear antigen 1 (EBNA1) protein induction of epithelial-mesenchymal transition in nasopharyngeal carcinoma cells","volume":"120","author":"Wang","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102840_b0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.coi.2017.07.004","article-title":"Vaccines targeting helper T cells for cancer immunotherapy","volume":"47","author":"Melssen","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ctrv.2024.102840_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1271236","article-title":"Cytotoxic CD4(+) T cells in chronic viral infections and cancer","volume":"14","author":"Malyshkina","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2024.102840_b0165","doi-asserted-by":"crossref","unstructured":"Akhmetzyanova I, Zelinskyy G, Littwitz-Salomon E, Malyshkina A, Dietze KK, Streeck H, Brandau S, Dittmer U: CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity. Journal of immunology (Baltimore, Md : 1950) 2016, 196(1):484-492.","DOI":"10.4049\/jimmunol.1403039"},{"issue":"1\u20132","key":"10.1016\/j.ctrv.2024.102840_b0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2012.02.013","article-title":"Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways","volume":"144","author":"Eshima","year":"2012","journal-title":"Immunol Lett"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102840_b0175","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/cas.13473","article-title":"Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma","volume":"109","author":"Yoshizaki","year":"2018","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102840_b0180","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"10.1016\/j.ctrv.2024.102840_b0185","first-page":"6952","article-title":"Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102840_b0190","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1080\/14712598.2019.1650910","article-title":"Immunotherapeutic approaches in nasopharyngeal carcinoma","volume":"19","author":"Chow","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ctrv.2024.102840_b0195","article-title":"Current status and advances of immunotherapy in nasopharyngeal carcinoma","volume":"14","author":"Xu","year":"2022","journal-title":"Therap Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102840_b0200","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41422-020-0374-x","article-title":"Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma","volume":"30","author":"Chen","year":"2020","journal-title":"Cell Res"},{"issue":"15","key":"10.1016\/j.ctrv.2024.102840_b0205","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1002\/cam4.3213","article-title":"Mechanisms of Epstein-Barr virus nuclear antigen 1 favor Tregs accumulation in nasopharyngeal carcinoma","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102840_b0210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.semcancer.2012.01.002","article-title":"Host-tumor interactions in nasopharyngeal carcinomas","volume":"22","author":"Gourzones","year":"2012","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102840_b0215","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri1936","article-title":"Cancer despite immunosurveillance: Immunoselection and immunosubversion","volume":"6","author":"Zitvogel","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"10.1016\/j.ctrv.2024.102840_b0220","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102840_b0225","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/eji.201444722","article-title":"Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy","volume":"45","author":"McDonnell","year":"2015","journal-title":"Eur J Immunol"},{"issue":"18","key":"10.1016\/j.ctrv.2024.102840_b0230","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1158\/1078-0432.CCR-10-0733","article-title":"A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers","volume":"16","author":"Kodumudi","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102840_b0235","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1084\/jem.20042167","article-title":"Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response","volume":"201","author":"Ercolini","year":"2005","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102840_b0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00262-020-02681-x","article-title":"Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1","volume":"70","author":"Makowska","year":"2021","journal-title":"Cancer Immunol Immunother : CII"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102840_b0245","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/09553009214551591","article-title":"Constraints on energy deposition and target size of multiply damaged sites associated with DNA double-strand breaks","volume":"61","author":"Brenner","year":"1992","journal-title":"Int J Radiat Biol"},{"issue":"2 Pt 1","key":"10.1016\/j.ctrv.2024.102840_b0250","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102840_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106663","article-title":"Abscopal effect in radioimmunotherapy","volume":"85","author":"Ashrafizadeh","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102840_b0260","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13014-019-1227-y","article-title":"Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects","volume":"14","author":"Tubin","year":"2019","journal-title":"Radiat Oncol (London, England)"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102840_b0265","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102840_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092458","article-title":"Radiotherapy combined with PD-1 inhibition increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells","volume":"10","author":"Makowska","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102840_b0275","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/neuros\/nyz198","article-title":"Radiotherapy, lymphopenia, and host immune capacity in glioblastoma: A potentially actionable toxicity associated with reduced efficacy of radiotherapy","volume":"85","author":"Kleinberg","year":"2019","journal-title":"Neurosurgery"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102840_b0280","article-title":"Preclinical immunoPET\/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma","volume":"6","author":"Kikuchi","year":"2017","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102840_b0285","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2024.102840_b0290","unstructured":"CSCO: GUIDELINES OF CHINESE SOCIETY OF CLINIC ONCOLOGY (CSCO) HEAD AND NECK CANCER 2024. [Internet]. Available from: https:\/\/meeting.csco.org.cn\/."},{"key":"10.1016\/j.ctrv.2024.102840_b0295","doi-asserted-by":"crossref","unstructured":"Chen Q-Y, Mai H-Q, Tang L-Q, Luo M, Zhao C, Mo H-Y, Sun R, Luo D-H, Wang L, Guo S-S et al: Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial. Journal of Clinical Oncology 2022, 40(16_suppl):6068-6068.","DOI":"10.1200\/JCO.2022.40.16_suppl.6068"},{"key":"10.1016\/j.ctrv.2024.102840_b0300","doi-asserted-by":"crossref","unstructured":"Liu SL, Mai H-Q, Wen D, Yang J-H, Guo S-S, Liu L-T, Luo M-J, Liang Y, Sun X-S, Li X-Y et al: Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial. Journal of Clinical Oncology 2024, 42(16_suppl):6084-6084.","DOI":"10.1200\/JCO.2024.42.16_suppl.6084"},{"key":"10.1016\/j.ctrv.2024.102840_b0305","doi-asserted-by":"crossref","unstructured":"Mai H-Q, Liu SL, Chen Q-Y, Tang L-Q, Jin F, Guo L, Luo H, Hu Y, Liu H, Liang J-H et al: Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial. Journal of Clinical Oncology 2024, 42(16_suppl):6001-6001.","DOI":"10.1200\/JCO.2024.42.16_suppl.6001"},{"key":"10.1016\/j.ctrv.2024.102840_b0310","doi-asserted-by":"crossref","unstructured":"Ma J, Sun Y, Liang Y-L, Liu X, Shen L, Hu W, Hu G, Xie F, Huang Y, Zou G et al: Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial. Journal of Clinical Oncology 2024, 42(17_suppl):LBA6000-LBA6000.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA6000"},{"issue":"10445","key":"10.1016\/j.ctrv.2024.102840_b0315","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ctrv.2024.102840_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.895187","article-title":"Efficacy and safety evaluation of sintilimab for cancer treatment: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Ye","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2024.102840_b0325","doi-asserted-by":"crossref","unstructured":"Hui EP, Ma B, Lim DW-T, Lam WKJ, Soong YL, Li L, Wong KCW, Lam D, Mok F, Tong M et al: NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC). Journal of Clinical Oncology 2023, 41(16_suppl):6010-6010.","DOI":"10.1200\/JCO.2023.41.16_suppl.6010"},{"key":"10.1016\/j.ctrv.2024.102840_b0330","doi-asserted-by":"crossref","unstructured":"Xu C, Shen L, Yang K-Y, Hu D, Chen X, Lin S, Jin F, Zhou Q, Peng G, Huang J et al: Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial. Journal of Clinical Oncology 2024, 42(16_suppl):6080-6080.","DOI":"10.1200\/JCO.2024.42.16_suppl.6080"},{"issue":"3\u20134","key":"10.1016\/j.ctrv.2024.102840_b0335","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbrc.2013.11.047","article-title":"An oncolytic adenovirus enhances antiangiogenic and antitumoral effects of a replication-deficient adenovirus encoding endostatin by rescuing its selective replication in nasopharyngeal carcinoma cells","volume":"442","author":"Liu","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"issue":"30","key":"10.1016\/j.ctrv.2024.102840_b0340","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","article-title":"A novel tetrameric gp350 1\u2013470 as a potential Epstein-Barr virus vaccine","volume":"31","author":"Cui","year":"2013","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.ctrv.2024.102840_b0345","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","article-title":"Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350","volume":"34","author":"Cui","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102840_b0350","doi-asserted-by":"crossref","first-page":"e976507","DOI":"10.4161\/23723556.2014.976507","article-title":"Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"4","author":"Li","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2024.102840_b0355","doi-asserted-by":"crossref","unstructured":"Liang YJ, Chen QY, Xu JX, Liu XF, Xia JC, Liu LT, Guo SS, Song B, Wang P, Li JB et al: A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients. European journal of cancer (Oxford, England : 1990) 2023, 191:112965.","DOI":"10.1016\/j.ejca.2023.112965"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T02:23:09Z","timestamp":1731637389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":71,"alternative-id":["S0305737224001683"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102840","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102840"}}